GlaxoSmithKline Pharmaceuticals reports Q1 FY26 PAT at Rs. 205 Cr
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
The performance was below anticipated levels, primarily due to external factors such as seasonal disruption that affected overall results
Mehta brings strong leadership experience in biopharmaceuticals, life science research, and diagnostics
Novo Nordisk will merge its Research & Early Development and Development functions into a single R&D unit
He has previously served in pivotal HR leadership roles at RPG Life Sciences, Akumentis Healthcare, and Wockhardt
His experience includes leadership roles in manufacturing, strategic management, and commercial operations across the pharmaceuticals, healthcare, and specialty chemicals sectors
Aman holds a bachelor’s degree in economics from Boston University and an MBA from Columbia University, New York
Prasad has played a key role in shaping Dr. Reddy’s into a globally respected organisation
Dr. Rao has over 29 years of experience in manufacturing, R&D, business operations, and customer service
Net profit doubled to Rs. 10.8 crore, with PAT margin expanding by 560 bps to 14.3%, reflecting strong operational execution
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
Subscribe To Our Newsletter & Stay Updated